{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:38:54Z","timestamp":1792759134797,"version":"4.5.0"},"reference-count":58,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      Clozapine is the gold-standard therapy for resistant schizophrenia. However, its use is limited by risks such as clozapine-induced agranulocytosis (CIA) and neutropenia (CIN), requiring strict monitoring. This study aimed to estimate the prevalence and mortality of CIA and CIN at\n                      <jats:italic toggle=\"yes\">GHU Paris Psychiatrie &amp; Neurosciences<\/jats:italic>\n                      and identify risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This retrospective study used data from the health data warehouse. We selected all patients treated with clozapine between January 1, 2019, and December 31, 2024. Based on the absolute neutrophil count (ANC), we identified cases of CIA (ANC\u2009&lt;\u2009500\/mm\n                      <jats:sup>3<\/jats:sup>\n                      ) and CIN, classified as mild (ANC\u2009=\u2009(1000\u20131499\/mm\n                      <jats:sup>3<\/jats:sup>\n                      )) or moderate (ANC\u2009=\u2009(500\u2013999\/mm\n                      <jats:sup>3<\/jats:sup>\n                      )). We then investigated risk factors using ordinal adjacent categories regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 1768 patients treated with clozapine, we identified 5 cases of CIA (prevalence: 0.28%), with no fatalities, and 163 cases of CIN (prevalence: 9.22%), including 36 moderate cases. African origins increased the risk of mild neutropenia (OR: 2.617; 95% CI: 1.327\u20135.163), while a higher ANC before treatment introduction decreased the risk (OR: 0.352; 95% CI: 0.229\u20130.542). Regarding the progression from mild to moderate neutropenia, receiving an anxiolytic treatment and being older than 49\u2009years old significantly decreased the risk (OR: 0.189, 95% CI: 0.042\u20130.86; OR: 0.139, 95% CI: 025\u20130.772, respectively). Treatment was discontinued in 44% of the patients with neutropenia, and 53% were rechallenged with clozapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study provides further evidence that CIA is a rare side effect. Given the benefits of clozapine and the rarity of agranulocytosis, our results suggest a looser approach to hematological monitoring and support the new French and US guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261449381","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:05:36Z","timestamp":1780038336000},"page":"1647-1659","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clozapine-induced neutropenia: Prevalence and associated factors"],"prefix":"10.1177","volume":"40","author":[{"given":"Veronica","family":"Sandroni","sequence":"first","affiliation":[{"name":"Institute of Psychiatry and Neuroscience of Paris (IPNP), Universit\u00e9 Paris Cit\u00e9, INSERM U1266, Team Pathophysiology of Psychiatric Disorders, CNRS GDR3557, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Sta","sequence":"additional","affiliation":[{"name":"GHU Paris Psychiatrie et Neurosciences, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Defez","sequence":"additional","affiliation":[{"name":"GHU Paris Psychiatrie et Neurosciences, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie B.","family":"S\u00e9bille","sequence":"additional","affiliation":[{"name":"GHU Paris Psychiatrie et Neurosciences, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Perozziello","sequence":"additional","affiliation":[{"name":"GHU Paris Psychiatrie et Neurosciences, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Iftimovici","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Neuroscience of Paris (IPNP), Universit\u00e9 Paris Cit\u00e9, INSERM U1266, Team Pathophysiology of Psychiatric Disorders, CNRS GDR3557, France"},{"name":"GHU Paris Psychiatrie et Neurosciences, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Chaumette","sequence":"additional","affiliation":[{"name":"GHU Paris Psychiatrie et Neurosciences, France"},{"name":"Department of Psychiatry, McGill University, Montr\u00e9al, QC, Canada"},{"name":"Institute of Psychiatry and Neuroscience of Paris (INSERM U1266), Universit\u00e9 Paris Cit\u00e9, Institut Pasteur (CNRS UMR3571), France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-3873","authenticated-orcid":false,"given":"Ariel","family":"Frajerman","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Neuroscience of Paris (IPNP), Universit\u00e9 Paris Cit\u00e9, INSERM U1266, Team Pathophysiology of Psychiatric Disorders, CNRS GDR3557, France"},{"name":"GHU Paris Psychiatrie et Neurosciences, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05785yel"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"e_1_3_5_4_1","unstructured":"ANSM (2025) Information de s\u00e9curit\u00e9\u2013Clozapine (Leponex et ses g\u00e9n\u00e9riques). Available at: https:\/\/ansm.sante.fr\/informations-de-securite\/clozapine-leponex-et-ses-generiques-mise-a-jour-des-recommandations-de-surveillance-de-la-numeration-formule-leucocytaire-nfl-pour-le-risque-dagranulocytose (accessed 8 March 2026)."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000060"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00440-1"},{"key":"e_1_3_5_8_1","unstructured":"Clozapine\u2013direct healthcare professional communication (DHPC) | European Medicines Agency (EMA) (2025). Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/clozapine (accessed 22 September 2025)."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09472-3"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21335"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2025.112747"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00366-8"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12193"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(14)70245-7"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201500507"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1167-0"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-022-00281-9"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01730-X"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211072341"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743718772522"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18com12123"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0911"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbl068"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.08.002"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14588"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2018-0188"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719000369"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001765"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.08.041"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008600"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12898"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867419833166"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1016669"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/S204579602200066X"},{"issue":"10","key":"e_1_3_5_37_1","first-page":"625","article-title":"The genetics of benign neutropenia","volume":"13","author":"Paz Z","year":"2011","unstructured":"Paz Z, Nails M, Ziv E (2011) The genetics of benign neutropenia. The Israel Medical Association Journal: IMAJ 13(10): 625\u2013629.","journal-title":"The Israel Medical Association Journal: IMAJ"},{"key":"e_1_3_5_38_1","unstructured":"R Core Team (2021)R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing Vienna. Available at: https:\/\/www.R-project.org"},{"key":"e_1_3_5_39_1","unstructured":"R Core Team. (2025) R A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. - References - Scientific Research Publishing (n.d.). Available at: https:\/\/www.scirp.org\/reference\/referencespapers?referenceid=3967248 (accessed 23 August 2025)."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L617"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13345"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000360"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717720448"},{"key":"e_1_3_5_44_1","volume-title":"Information on clozapine","author":"Research C","year":"2025","unstructured":"Research C (2025) Information on clozapine. U.S. Food and Drug Administration. Epub ahead of print 25 February 2025."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.06.070"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40596-019-01134-7"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717718167"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00098-7"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00098-7"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070817"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834405fc"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02138-4"},{"key":"e_1_3_5_53_1","article-title":"Blood dyscrasias induced by psychotropic drugs","volume":"37","author":"St\u00fcbner S","year":"2004","unstructured":"St\u00fcbner S, Grohmann R, Engel R, et al. (2004) Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 37: S70\u2013S78.","journal-title":"Pharmacopsychiatry"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00366-3"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000086"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby052"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04659-2"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v032.i10"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16141-5"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261449381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261449381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261449381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:51:00Z","timestamp":1792756260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261449381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/02698811261449381"],"URL":"https:\/\/doi.org\/10.1177\/02698811261449381","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}